Bloomage Biotechnology reports asset impairment, profit growth despite revenue dip

Bloomage Biotechnology Corporation reported asset impairment provisions totaling 2,325.08 million yuan for the third quarter of 2025. This included 1,753.78 million yuan for credit impairment losses on accounts receivable and other receivables, and 571.30 million yuan for inventory depreciation. Despite these provisions, the company's Q3 2025 net profit attributable to shareholders increased by 55.63% to 31,528,454.35 yuan, despite a 15.16% decrease in operating revenue compared to the previous year.

The company's operational efficiency showed improvement, with an 858.55% increase in net cash flow from operating activities, reaching 90,426,773.22 yuan for the quarter. Selling expenses as a percentage of revenue decreased to 34.26%, the lowest in five years, driven by optimized brand communication and channel structures.

For the first three quarters of 2025, Bloomage Biotechnology's net profit attributable to shareholders reached 252,380,359.37 yuan, despite a 30.29% year-over-year decrease. The company emphasized its strategic focus on synthetic biology and a "raw material-end product" integrated business model, particularly in anti-aging, to drive future growth. These impairment provisions reflect the company's cautious financial policy and do not alter its overall profitability.